BioSpace News Archive

Astria Therapeutics, Inc. today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Wedbush PacGrow Healthcare Conference on Wednesday, August 10, at 9:10am ET.

Twist Bioscience Corporation today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Flash Memory Summit taking place August 2-4, 2022 at the Santa Clara Convention Center in Santa Clara, CA.

Societal CDMO, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced that the company will release financial results for the second quarter 2022 after the market close on Wednesday, August 10, 2022.

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, reported financial results for the second quarter of 2022 and recent corporate updates.

REGENXBIO Inc. announced financial results for the second quarter ended June 30, 2022, and recent operational highlights.

Berkeley Lights, Inc., a leader in digital cell biology, announced its participation at the Cambridge Healthtech Institute’s 14th Annual Bioprocessing Summit being held from August 15 - 18, 2022, virtually and at the Sheraton Boston in Boston, Massachusetts.

PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2022.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that Pascal Touchon, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 9:00 a.m. PDT / 12:00 p.m. EDT.

Arcus Biosciences, Inc. (NYSE:RCUS), today reported financial results for the second quarter ended June 30, 2022 and provided a pipeline update on its six clinical-stage molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b), HIF-2a and PD-1 – across multiple common cancers.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2022.